Archives
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
To further investigate the relationship between the pro neur
2021-10-15

To further investigate the relationship between the pro-neurogenic and therapeutic actions, we analyzed the effect of VP2.51 in the presence of the antimitotic agent TMZ. No overt side effects were found at the time of testing as assessed by direct observation of the behavior of the animals in their
-
The compounds f and a e were found to be
2021-10-15

The compounds 8f and 9a–e were found to be potent inhibitors of both isoforms of GSK-3 as characterized by IC50 values in the low nanomolar range. In addition, all of them showed good selectivities against other kinases. Substituents in the ortho- and para-positions of structure 8 and 9 lead to pote
-
br GSK Glycogen synthase kinase GSK
2021-10-15

GSK-3 Glycogen synthase kinase-3 (GSK-3) is a ubiquitous serine/threonine kinase that is involved in multiple signaling pathways that are crucial for cellular metabolism and proliferation (Doble and Woodgett, 2003, Frame and Cohen, 2001, Grimes and Jope, 2001, Woodgett, 1990). GSK-3 is known to d
-
br Material and methods br Results
2021-10-15

Material and methods Results Discussion Functional characterization of naturally occurring GCK mutations in patients with impaired glucose homeostasis has widened our knowledge of the catalytic and regulatory mechanisms of this enzyme [3]. In this work, we have biochemically characterized a
-
While CART increased circulating levels of GIP
2021-10-15

While CART increased circulating levels of GIP and GLP-1 in vivo, we were unable to detect any effect of exogenous CART on GIP and GLP-1 mRNA expression or GLP-1 secretion in vitro. There is no ready explanation for this discrepancy. The CART doses used (both in vivo and in vitro) have been shown to
-
It is widely acknowledged that CpG methylation of the
2021-10-15

It is widely acknowledged that CpG methylation of the promoter regions of some genes plays an important regulatory role in transcriptional regulation and in the establishment and maintenance of cell type-specific gene expression (Li, 2002, Jaenisch and Bird, 2003). This study obtained multiple lines
-
340 7 australia br Materials and methods br Results br Discu
2021-10-14

Materials and methods Results Discussion FFAR4 is a G-protein coupled free fatty 340 7 australia receptor that has been reported to be expressed in osteoclasts and osteoblasts [18]. In this study the role of FFAR4 on the effects of different classes of UFAs, the ω−6 PUFA, AA, the ω−3 PUFAs
-
br Acknowledgements We thank Kathy Spindler for
2021-10-14

Acknowledgements We thank Kathy Spindler for helpful review of the manuscript. Expert technical assistance from Joel Whitfield in the University of Michigan Cancer Center Immunology Core is greatly appreciated. This research was supported by the American Heart Association (16GRNT30250013) and by
-
br Drug design Over the past decades
2021-10-14

Drug design Over the past decades, the development of synthetic, direct fXa inhibitors has undergone four phase. Although these fXa inhibitors possess various scaffolds, most of them bind to the active site in a characteristic l-shaped conformation. In other word, they have a three-component syst
-
It is apparent from the data in
2021-10-14

It is apparent from the data in that none of the ligands exhibits significant toxicity as determined by the viability of human embryonic kidney (HEK 293) cells at a concentration of 100 μM. It is also apparent from the data in and that a number of the ligands inhibit the HIV-1 IN enzyme. However,
-
Hypoxia HIF and Inflammation Cellular responses to hypoxia
2021-10-14

Hypoxia, HIF, and Inflammation Cellular responses to hypoxia are essential for life and are now recognized to be dysregulated in a wide range of disease processes. The key players in these pathways are a family of transcription factors, the hypoxia-inducible factors (HIFs; see Glossary), as well as
-
Several classes of small molecules that modulate CDK
2021-10-14

Several classes of small molecules that modulate CDK8 activity have been reported in the patent literature (Fig. 1). A quinazoline derivative, Senexin B (SNX2-1–165, 1), showed CDK8 enzyme inhibitory activity with an IC50 value of 24–50 nM in different assay, and displayed potent, selective enzymati
-
br Acknowledgements This work has been
2021-10-14

Acknowledgements This work has been supported by TSTAR USDA and Florida Citrus Advanced Technology Program Grants to D.B., C.P and R.S. One of us (D.B.) is an established scientist fellow at the Oak Ridge Institute for Science and Education (ORISE). This research was supported in part by an appoi
-
It is an open question if
2021-10-14

It is an open question if these in vitro findings have implications for the use of sGC activators in the in vivo situation and in patients. Assuming that incorporation in de novo synthesised enzyme occurs during therapy, one might speculate that the duration of drug administration has an influence o
-
In diseased blood vessels increased production of
2021-10-14

In diseased blood vessels, increased production of reactive oxygen species (ROS), such as peroxynitrite, superoxide, and hydrogen peroxide, have been found [[53], [54], [55]]. Peroxynitrite was suggested to alter the redox state of sGC [53] while hydrogen peroxide interfered with the action of NO bu
16043 records 552/1070 page Previous Next First page 上5页 551552553554555 下5页 Last page